Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
PRPH 
ProPhase Labs Inc (PRPH)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/15/2025: PRPH (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $13.8
1 Year Target Price $13.8
| 1 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -58.87% | Avg. Invested days 21 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/15/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 19.61M USD | Price to earnings Ratio - | 1Y Target Price 13.8 |
Price to earnings Ratio - | 1Y Target Price 13.8 | ||
Volume (30-day avg) 1 | Beta -0.6 | 52 Weeks Range 0.22 - 2.50 | Updated Date 10/15/2025 |
52 Weeks Range 0.22 - 2.50 | Updated Date 10/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.07 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -312.27% |
Management Effectiveness
Return on Assets (TTM) -28.85% | Return on Equity (TTM) -171.81% |
Valuation
Trailing PE - | Forward PE 10.09 | Enterprise Value 30409730 | Price to Sales(TTM) 3.51 |
Enterprise Value 30409730 | Price to Sales(TTM) 3.51 | ||
Enterprise Value to Revenue 5.44 | Enterprise Value to EBITDA 2.45 | Shares Outstanding 41541205 | Shares Floating 38222063 |
Shares Outstanding 41541205 | Shares Floating 38222063 | ||
Percent Insiders 7.99 | Percent Institutions 6.57 |
Upturn AI SWOT
ProPhase Labs Inc
Company Overview
History and Background
ProPhase Labs, Inc. was founded in 1987. Initially focused on contract manufacturing and private label OTC drugs, they shifted towards diagnostics, particularly COVID-19 testing, and expanded into genomic testing through acquisitions. They also ventured into the marketing and distribution of consumer healthcare products.
Core Business Areas
- Diagnostics: COVID-19 testing services, including PCR and rapid antigen testing. Expanded to include other infectious disease testing.
- Genomics: DNA testing services for inherited cancer risk, pharmacogenomics, and personalized medicine.
- Consumer Healthcare: Marketing and distribution of BE-ATTITUDE skincare products.
Leadership and Structure
Ted Karkus is the CEO. The organizational structure includes operational, sales, and marketing teams, with dedicated departments for diagnostics, genomics, and consumer healthcare.
Top Products and Market Share
Key Offerings
- Product Name 1: COVID-19 Testing: ProPhase Labs provided COVID-19 testing services, especially during the pandemic peak. Market share fluctuated with demand and competition. Competitors include Labcorp (LH) and Quest Diagnostics (DGX).
- Product Name 2: PGxOne DNA Testing: DNA testing for personalized medicine and pharmacogenomics. Market share is relatively small but growing in the personalized medicine sector. Competitors include Myriad Genetics (MYGN) and Invitae (NVTA).
- Product Name 3: BE-ATTITUDE: Skincare products. ProPhase Labs, Inc. acquired this to sell to the beauty market. Competitors include Estee Lauder (EL) and L'Oreal (OR.PA).
Market Dynamics
Industry Overview
The diagnostics market is characterized by rapid technological advancements and increasing demand for personalized medicine and preventative healthcare. The consumer healthcare market is highly competitive and driven by consumer trends.
Positioning
ProPhase Labs Inc. is positioning itself as a provider of diagnostic testing and personalized medicine solutions, as well as consumer healthcare products. They aim to capture growth through strategic acquisitions and market expansion.
Total Addressable Market (TAM)
The combined TAM for diagnostics, genomics, and consumer healthcare is substantial, potentially reaching hundreds of billions of dollars globally. ProPhase Labs Inc. is positioned to capture a small fraction of this market with their specific offerings.
Upturn SWOT Analysis
Strengths
- Diversified Revenue Streams
- Strategic Acquisitions
- Experience in Diagnostics
- Established Distribution Network
Weaknesses
- High Debt Levels
- Dependence on COVID-19 Testing Revenue
- Limited Brand Recognition
- Volatile Stock Price
Opportunities
- Expansion into New Diagnostic Tests
- Partnerships with Healthcare Providers
- Increased Demand for Personalized Medicine
- Growing Skincare Market
Threats
- Increased Competition
- Changes in Government Regulations
- Declining COVID-19 Testing Demand
- Economic Downturn
Competitors and Market Share
Key Competitors
- LH
- DGX
- MYGN
- NVTA
Competitive Landscape
ProPhase Labs Inc. faces intense competition from larger, more established players in the diagnostics and genomics industries. Its competitive advantage lies in its diversified revenue streams and strategic acquisitions.
Major Acquisitions
Neuberg Virchow Group's U.S. Assets
- Year: 2023
- Acquisition Price (USD millions): 17.5
- Strategic Rationale: Expanded the company's laboratory testing services and geographic reach.
BE-ATTITUDE
- Year: 2023
- Acquisition Price (USD millions): 1
- Strategic Rationale: Expanded the company into the beauty/skincare market.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been driven by acquisitions and the surge in COVID-19 testing demand.
Future Projections: Future growth will depend on the company's ability to diversify its revenue streams and capitalize on opportunities in personalized medicine and consumer healthcare. Analyst estimates are not available without financial services access.
Recent Initiatives: Recent strategic initiatives include expanding genomic testing services, acquiring skincare product lines, and partnering with healthcare providers.
Summary
ProPhase Labs Inc. is a dynamic company undergoing significant transformation, and shifting markets. While strategic acquisitions have broadened its scope, high debt and reliance on testing pose challenges. Expanding genomic offerings and growing the Be-Attitude brand represents future opportunities, yet the business must navigate a competitive landscape and changing regulatory environment to secure sustainable growth.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- Company SEC Filings
- Industry Reports
- Financial News Outlets
Disclaimers:
This analysis is based on publicly available information and should not be considered financial advice. Financial data may be delayed. Market share data are estimates and may vary. The AI-based rating is for informational purposes only and does not guarantee future performance.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About ProPhase Labs Inc
Exchange NASDAQ | Headquaters Garden City, NY, United States | ||
IPO Launch date 1997-01-16 | Chairman & CEO Mr. Ted William Karkus | ||
Sector Healthcare | Industry Diagnostics & Research | Full time employees 96 | Website https://www.prophaselabs.com |
Full time employees 96 | Website https://www.prophaselabs.com | ||
ProPhase Labs, Inc. develops and commercializes novel drugs, dietary supplements, and compounds in the United States. It operates through two segments: Diagnostic Services and Consumer Products. The company provides a range of dietary supplements under the TK supplements, including Legendz XL, a male sexual enhancement; and Triple Edge XL, an energy and stamina booster. It also develops BE-Smart Esophageal Pre-Cancer diagnostics screening test for early detection of esophageal cancer; genomics testing technologies to analyze entire genomes, including the genes and chromosomes in deoxyribonucleic acid; DNA Expand, a platform that allows consumers to upload their DNA data from previous DNA tests obtained from other service providers; and LB-1 and LB-2 for the treatment of cancer, inflammatory diseases or symptoms and memory related syndromes, diseases or symptoms, including dementia and Alzheimer's disease. In addition, the company provides a broad range of COVID-19 related clinical diagnostic and testing services, comprising PCR testing for COVID-19, and Influenza A and B, as well as rapid antigen testing for COVID-19. It offers its genome sequencing products to consumers online with plans to sell in food, drug, and mass retail stores. The company was formerly known as The Quigley Corporation. ProPhase Labs, Inc. was founded in 1989 and is headquartered in Garden City, New York.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.